Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Stoke Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +4 vs. Q2 2024
- Shares held
- 58.2M
- +2.30M (+4.1%) vs. Q2 2024
- Total value
- $715.5M
- −$40.0M (−5.3%) vs. Q2 2024
- New holders
- 24
- 38 more added
- Sold out
- 20
- 36 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STOK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $2.49B |
| Q1 2026 | 198 | $2.31B |
| Q4 2025 | 183 | $2.13B |
| Q3 2025 | 151 | $1.57B |
| Q2 2025 | 134 | $744.0M |
| Q1 2025 | 126 | $421.6M |
| Q4 2024 | 130 | $640.4M |
| Q3 2024 | 118 | $715.5M |
| Q2 2024 | 115 | $828.5M |
| Q1 2024 | 103 | $731.7M |
| Q4 2023 | 81 | $236.9M |
| Q3 2023 | 97 | $173.1M |
| Q2 2023 | 100 | $494.8M |
| Q1 2023 | 97 | $371.8M |
| Q4 2022 | 107 | $371.8M |
| Q3 2022 | 105 | $544.4M |
| Q2 2022 | 92 | $569.4M |
| Q1 2022 | 99 | $870.6M |
| Q4 2021 | 94 | $849.6M |
| Q3 2021 | 90 | $492.4M |
| Q2 2021 | 97 | $680.3M |
| Q1 2021 | 106 | $1.49B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Stoke Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 427,163 | $5.25M | 0.28% | 00.0% | Unchanged |
| Deutsche Bank AG | 462,475 | $5.68M | 0.00% | +446,445+2,785.1% | Added |
| MPM Oncology Impact Management LP | 479,452 | $5.89M | 0.88% | +479,452 | New |
| Granahan Investment Management Inc | 644,970 | $7.93M | 0.31% | +46,569+7.8% | Added |
| Geode Capital Management, LLC | 870,831 | $10.7M | 0.00% | +76,661+9.7% | Added |
| Assenagon Asset Management S.A. | 1,312,479 | $16.1M | 0.03% | −155,723−10.6% | Reduced |
| Goldman Sachs Group Inc | 1,393,760 | $17.1M | 0.00% | +26,243+1.9% | Added |
| Marshall Wace, LLP | 1,670,733 | $20.5M | 0.03% | +509,696+43.9% | Added |
| State Street Corp | 1,728,888 | $21.2M | 0.00% | +137,145+8.6% | Added |
| Vanguard Group Inc | 2,759,247 | $33.9M | 0.00% | +71,589+2.7% | Added |
| Cowen and Company, LLC | 3,244,498 | $39.9M | 1.38% | −121,246−3.6% | Reduced |
| Morgan Stanley | 4,205,307 | $51.7M | 0.00% | +726,510+20.9% | Added |
| Baker Bros. Advisors LP | 4,368,443 | $53.7M | 0.56% | 00.0% | Unchanged |
| RTW Investments, LP | 4,652,285 | $57.2M | 0.83% | +427,447+10.1% | Added |
| Redmile Group, LLC | 4,713,509 | $57.9M | 3.41% | −7,545−0.2% | Reduced |
| Lynx1 Capital Management LP | 5,187,191 | $63.8M | 22.59% | +2,0000.0% | Added |
| BlackRock, Inc. | 5,570,150 | $68.5M | 0.00% | +5,570,150 | New |
| Skorpios Trust | 8,906,181 | $109.5M | 99.85% | −1,937,500−17.9% | Reduced |
| Healthcare of Ontario Pension Plan Trust Fund | 0 | $0 | 0.00% | −1,387,200−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −1,050,000−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −437,136−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −175,301−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −141,518−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −126,830−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −59,149−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −46,059−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −44,205−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −43,424−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −34,277−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −25,926−100.0% | Sold out |
| Chase Investment Counsel Corp | 0 | $0 | 0.00% | −20,738−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −18,402−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,200−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −1,527−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −454−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −173−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −118−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |